WO2012127501A3 - Composition pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne - Google Patents

Composition pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne Download PDF

Info

Publication number
WO2012127501A3
WO2012127501A3 PCT/IN2012/000166 IN2012000166W WO2012127501A3 WO 2012127501 A3 WO2012127501 A3 WO 2012127501A3 IN 2012000166 W IN2012000166 W IN 2012000166W WO 2012127501 A3 WO2012127501 A3 WO 2012127501A3
Authority
WO
WIPO (PCT)
Prior art keywords
thickness during
ovarian stimulation
composition
highly purified
during ovarian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2012/000166
Other languages
English (en)
Other versions
WO2012127501A2 (fr
Inventor
Prasad K.V.S.
L. Soman JAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANZYME Ltd
Original Assignee
SANZYME Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANZYME Ltd filed Critical SANZYME Ltd
Publication of WO2012127501A2 publication Critical patent/WO2012127501A2/fr
Publication of WO2012127501A3 publication Critical patent/WO2012127501A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une combinaison d'hormone de stimulation folliculaire (FSH) hautement purifiée et d'une gonadotropine chorionique humaine (HCG) hautement purifiée pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne. En particulier, l'invention concerne également une composition pour améliorer l'épaisseur de l'endomètre au cours de la stimulation ovarienne, comprenant une combinaison de 5 IU à 50 IU de FSH hautement purifiée et de 50 IU à 1000 IU de hCG hautement purifiée par dose ainsi que des préparations pharmaceutiques les comprenant.
PCT/IN2012/000166 2011-03-11 2012-03-12 Composition pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne Ceased WO2012127501A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN693MU2011 2011-03-11
IN693/MUM/2011 2011-03-11

Publications (2)

Publication Number Publication Date
WO2012127501A2 WO2012127501A2 (fr) 2012-09-27
WO2012127501A3 true WO2012127501A3 (fr) 2013-03-21

Family

ID=46879830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000166 Ceased WO2012127501A2 (fr) 2011-03-11 2012-03-12 Composition pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne

Country Status (1)

Country Link
WO (1) WO2012127501A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (fr) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2019211153A1 (fr) * 2018-04-30 2019-11-07 Ferring B.V. Composition destinée à la stimulation ovarienne contrôlée
CN110787286B (zh) * 2019-11-21 2024-06-25 重庆市畜牧科学院 Fsh和hcg在制备促进睾丸细胞功能恢复的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929028A (en) * 1997-01-15 1999-07-27 Akzo Nobel, N.V. Liquid gonadotropin containing formulations
US20040204393A1 (en) * 2001-04-17 2004-10-14 Casper Robert F. Aromatase inhibition to enhance assisted reproduction
US20040224895A1 (en) * 1999-05-07 2004-11-11 Applied Research Systems Ars Holding N.V. Gonadotrophins
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2007056851A1 (fr) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions et procedes visant a ameliorer les agents inducteurs de l'ovulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929028A (en) * 1997-01-15 1999-07-27 Akzo Nobel, N.V. Liquid gonadotropin containing formulations
US20040224895A1 (en) * 1999-05-07 2004-11-11 Applied Research Systems Ars Holding N.V. Gonadotrophins
US20040204393A1 (en) * 2001-04-17 2004-10-14 Casper Robert F. Aromatase inhibition to enhance assisted reproduction
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2007056851A1 (fr) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions et procedes visant a ameliorer les agents inducteurs de l'ovulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOMAN ET AL.: "Endotoxin Levels and Mouse Embryo Development in Two Commercially Available IVF media.", ABSTRACTS OF THE 12TH ANNUAL MEETING OF THE EHSRE, 1996, MAASTRICHT *

Also Published As

Publication number Publication date
WO2012127501A2 (fr) 2012-09-27

Similar Documents

Publication Publication Date Title
UA99337C2 (ru) Жидкая лекарственная форма фсг
WO2011041694A3 (fr) Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011017350A3 (fr) Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
WO2011041461A3 (fr) Composés polycycliques utiles en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
WO2010141761A3 (fr) Antagonistes polycycliques de récepteurs d'acide lysophosphatidique
WO2011062437A3 (fr) Antagonistes des récepteurs de l'hormone de libération des gonadotrophines, leurs procédés de production et composition pharmaceutique les contenant
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
WO2010077882A3 (fr) Antagonistes des récepteurs d'acide lysophosphatidique
WO2010068775A3 (fr) Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique
MY153976A (en) Lh liquid formulations
MX2024008825A (es) Composicion para la estimulacion ovarica controlada.
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
IN2015DN00528A (fr)
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
MX2013009459A (es) Preparacion farmaceutica que contiene selenita o compuestos que contienen selenita para el tratamiento de displasias cervicales o carcinomas.
FI2621517T4 (fi) Koostumus käytettäväksi hedelmättömyyden hoidossa
MX362905B (es) Tratamiento de combinacion.
GB2530226A (en) Chewable tablet
WO2012004588A3 (fr) Agents thérapeutiques 976
NZ609804A (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
WO2012127500A3 (fr) Composition pour la spermatogenèse
WO2009075838A3 (fr) Traitement de la ménorragie avec un inhibiteur de l'aromatase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760525

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12760525

Country of ref document: EP

Kind code of ref document: A2